This invention involves the production, application, and uptake assessment of salmochelin conjugated with cholera toxin B (CTB) or keyhole limpet hemocyanin (KLH), immune-stimulating carrier proteins. The conjugates were produced with PEG3 linkers connected CTB to the salmochelin using a peptide coupling strategy to bond lysine residues on the carrier protein to a free carboxylic acid on the PEG3 linker. Mice immunized intranasally with the conjugate were observed to possess antibodies against salmochelin in circulation for up to 51 days after the first immunization, with a novel ELISA. Immunized mice showed less weight loss after infection with Salmonella typhimurium and colonization within the intestines of the infected mice correlated with the amount IgA detected in the novel ELISA. Finally, microbiota assessment of the immunized mice revealed substantially lower levels of the pathogenic Salmonella and higher levels of beneficial microbes like Lactobacillus.